NSCLC Adenocarcinoma Clinical Trials
2 recruiting trials for NSCLC Adenocarcinoma. Eligibility criteria explained in plain English.
TrialFinderData lists 2 NSCLC Adenocarcinoma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 1 (2 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by MacroGenics (1), IDEAYA Biosciences (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is MGC028 (biological, 1 trial), followed by IDE892, IDE397.
Track NSCLC Adenocarcinoma trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study of MGC028 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of...
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for NSCLC Adenocarcinoma, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for NSCLC Adenocarcinoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for NSCLC Adenocarcinoma, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.